BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23380533)

  • 1. The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
    Thomas Tayra J; Kameda M; Yasuhara T; Agari T; Kadota T; Wang F; Kikuchi Y; Liang H; Shinko A; Wakamori T; Vcelar B; Weik R; Date I
    Brain Res; 2013 Mar; 1502():55-70. PubMed ID: 23380533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
    Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.
    Kadota T; Shingo T; Yasuhara T; Tajiri N; Kondo A; Morimoto T; Yuan WJ; Wang F; Baba T; Tokunaga K; Miyoshi Y; Date I
    Brain Res; 2009 Feb; 1254():120-7. PubMed ID: 19101524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise exerts neuroprotective effects on Parkinson's disease model of rats.
    Tajiri N; Yasuhara T; Shingo T; Kondo A; Yuan W; Kadota T; Wang F; Baba T; Tayra JT; Morimoto T; Jing M; Kikuchi Y; Kuramoto S; Agari T; Miyoshi Y; Fujino H; Obata F; Takeda I; Furuta T; Date I
    Brain Res; 2010 Jan; 1310():200-7. PubMed ID: 19900418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
    Xue YQ; Zhao LR; Guo WP; Duan WM
    Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
    Georgievska B; Carlsson T; Lacar B; Winkler C; Kirik D
    Eur J Neurosci; 2004 Dec; 20(11):3121-30. PubMed ID: 15579166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Agrawal AK
    Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
    Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R; Mohapel P; Brundin P; Paul G
    Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
    Dusonchet J; Bensadoun JC; Schneider BL; Aebischer P
    Neurobiol Dis; 2009 Jul; 35(1):32-41. PubMed ID: 19348945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.